10-K: Sangamo Therapeutics Faces Going Concern Uncertainty Despite Collaboration Deals

Sangamo Therapeutics reports a net loss and expresses substantial doubt about its ability to continue as a going concern, even with recent collaboration agreements.

Summary

• Sangamo Therapeutics reports a net loss of $97.9 million for 2024 and expresses substantial doubt about its ability to continue as a going concern.
• The company's ability to continue operations depends on securing additional funding through collaborations, equity or debt financing.
• Sangamo has been actively seeking additional capital, but faces challenges due to market conditions and the speculative nature of its neurology programs.
• The company's cash and cash equivalents are expected to meet liquidity requirements only into the middle of the second quarter of 2025.
• Recent collaboration agreements with Genentech and Astellas provide upfront payments and potential future milestones, but may not be sufficient to fully fund operations.
• The company is exploring options, including potential bankruptcy protection, to address its financial challenges.
• Sangamo is focused on core preclinical neurology programs and capsid engineering platform.
• The company has completed enrollment in the Phase 1/2 STAAR study for Fabry disease and anticipates a BLA submission in the second half of 2025.
• Pfizer terminated its collaboration agreement for hemophilia A, but Sangamo is scheduled to regain development and commercialization rights.
• The company is seeking a new collaboration partner for the hemophilia A program.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation for Sangamo Therapeutics, with a net loss, going concern uncertainty, and reliance on securing additional funding. While there are some positive developments in the pipeline, the overall tone is negative due to the financial challenges.

Positives

• FDA cleared the IND for ST-503 for the treatment of intractable pain due to iSFN.
• The company is preparing for the Phase 1/2 clinical study to assess the safety, tolerability and preliminary efficacy of a one-time dose of ST-503, administered intrathecally to patients with intractable pain due to iSFN, and expect to commence the enrollment and dosing of patients in mid-2025, subject to our ability to secure adequate additional funding.
• The company has completed enrollment in the Phase 1/2 STAAR study for Fabry disease and anticipates a BLA submission in the second half of 2025.
• Pfizer terminated its collaboration agreement for hemophilia A, but Sangamo is scheduled to regain development and commercialization rights.
• The company is seeking a new collaboration partner for the hemophilia A program.
• The company entered into a license agreement with Astellas Gene Therapies, Inc., or Astellas, allowing Astellas to leverage our novel AAV capsid, STAC-BBB. The Astellas Agreement grants Astellas a worldwide exclusive license to utilize the STAC-BBB capsid for one target, with the right for Astellas to add up to four additional targets after paying us additional licensed target fees to deliver their intravenously administered genomic medicines to treat certain neurological diseases.

Negatives

• Sangamo Therapeutics reports a net loss of $97.9 million for 2024 and expresses substantial doubt about its ability to continue as a going concern.
• The company's cash and cash equivalents are expected to meet liquidity requirements only into the middle of the second quarter of 2025.
• Pfizer terminated its collaboration agreement for hemophilia A.
• The company is exploring options, including potential bankruptcy protection, to address its financial challenges.

Risks

• There is substantial doubt about Sangamo's ability to continue as a going concern.
• The company needs substantial additional funding to execute its operating plan.
• Failure to obtain adequate funding could lead to cost reduction measures, reduced R&D activities, or cessation of operations.
• Future sales and issuances of equity securities would result in substantial dilution to stockholders.
• The company's ability to continue funding operations depends on securing collaboration partners.
• The company is a biotechnology company with no approved products or product revenues.
• The company has historically incurred significant operating losses since inception and anticipate continued losses for the foreseeable future.
• The company may never become profitable.
• The company's stock price has been volatile and will likely continue to be volatile, which could result in substantial losses for investors and potentially class action securities litigation against us, and could be influenced by public perception of genomic medicines and the biotechnology sector.

Future Outlook

Sangamo expects research and development expenses to increase in the near-term due to Fabry disease program BLA readiness activities and expects to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in raising substantial additional capital and advancing our product candidates from research stage through clinical trials.

Management Comments

• Management expresses substantial doubt about the company's ability to continue as a going concern.
• Management is actively seeking additional capital through various means, including strategic collaborations and equity or debt financing.

Industry Context

The document highlights the competitive nature of the biotechnology and genomic medicine industries, with several companies focused on similar technologies and product candidates. It also mentions the increasing regulatory scrutiny and the potential impact of healthcare reform on pricing and reimbursement.

Comparison to Industry Standards

• The document mentions several competitors in the gene therapy and genome editing space, including BioMarin Pharmaceutical, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Beam Therapeutics.
• It also notes competition in AAV capsid technologies from companies like 4D Molecular Therapeutics, Affinia Therapeutics, Capsida Biotherapeutics, and Dyno Therapeutics.
• The document does not provide a direct comparison of Sangamo's results to specific industry benchmarks, but it does mention that the company's product candidates will compete with existing products that have long histories of safe and effective use.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances and the risk of losing their investment if the company cannot continue as a going concern.
• Employees face uncertainty due to potential cost reduction measures and workforce reductions.
• Patients may experience delays in the development and commercialization of new therapies.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company expects to commence the enrollment and dosing of patients in mid-2025, subject to our ability to secure adequate additional funding.
• A CTA submission for the prion program is expected in the first quarter of 2026, subject to our ability to secure adequate additional funding.
• The 52-week eGFR slope data from all enrolled patients in the Phase 1/2 STAAR study will be available in the first half of 2025 and a potential Biologics License Application, or BLA, submission is anticipated in the second half of 2025.
• We continue to explore how to maximize the value of the SB-525 program, including a search for a potential new collaboration partner.

Key Dates